Soligenix

Soligenix is a late-stage biopharmaceutical company based in Princeton, New Jersey, with 23 employees. The company focuses on developing and commercializing products to treat rare diseases with unmet medical needs. Soligenix has two main business segments. Their Specialized BioTherapeutics segment develops and commercializes HyBryte™, a novel photodynamic therapy using safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). This segment also includes development programs for synthetic hypericin (SGX302) for psoriasis, dusquetide (SGX942) for inflammatory diseases, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for gastrointestinal disorders. Their Public Health Solutions segment focuses on vaccine development, including RiVax®, a ricin toxin vaccine candidate, and vaccine programs targeting filoviruses (Marburg and Ebola) and coronaviruses (COVID-19; CiVax™). This segment also includes SGX943, a therapeutic candidate for antibiotic-resistant and emerging infectious diseases. Soligenix employs a proprietary heat stabilization platform technology called ThermoVax® in its vaccine development. Their Public Health Solutions segment has received funding from government agencies such as the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA). For more information, visit Soligenix's website at soligenix.com.